Information Provided By:
Fly News Breaks for September 6, 2017
MDXG
Sep 6, 2017 | 07:55 EDT
After MiMedx announced that its venous leg ulcer, or VLU, randomized controlled trial was accepted for publication in The International Wound Journal, Needham analyst Mike Matson thinks the results are favorable versus a competing treatment, Organogenesis Apligraf. He estimates that coverage of the VLU indication could generate $75M-$150M of incremental revenue for MiMedx in 2018. He raised his price target on the shares to $21 from $20 and keeps a Strong Buy rating on the stock.